BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding AS, Routkevitch D, Jackson C, Lim M. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Front Immunol 2019;10:1715. [PMID: 31396227 DOI: 10.3389/fimmu.2019.01715] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Kalluri AL, Shah PP, Lim M. The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches. IJMS 2023;24:2020. [DOI: 10.3390/ijms24032020] [Reference Citation Analysis]
2 Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD, Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F, Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh Z. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines (Basel) 2022;10:1448. [PMID: 36146527 DOI: 10.3390/vaccines10091448] [Reference Citation Analysis]
3 Xu H, Feng Y, Kong W, Wang H, Feng Y, Zhen J, Tian L, Yuan K. High Expression Levels of SIGLEC9 Indicate Poor Outcomes of Glioma and Correlate With Immune Cell Infiltration. Front Oncol 2022;12:878849. [PMID: 35756603 DOI: 10.3389/fonc.2022.878849] [Reference Citation Analysis]
4 Zhao Z, Wang Z, Wu Y, Liao D, Zhao B. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response. Molecular Immunology 2022;144:78-95. [DOI: 10.1016/j.molimm.2022.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Exley MA, Garcia S, Zellander A, Zilberberg J, Andrews DW. Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma. J Clin Med 2022;11:1069. [PMID: 35207340 DOI: 10.3390/jcm11041069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao Z, Zhao J, Wang Z, Wu Y, Zhang Z, Song Z, Miao J, Liu B, Zhang S, Sun B, Zhao Z. Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment. Int J Immunopathol Pharmacol 2022;36:3946320221104548. [PMID: 35609253 DOI: 10.1177/03946320221104548] [Reference Citation Analysis]
7 Chuntova P, Watchmaker PB, Gilbert R, Okada H. Immunomodulatory roles of myeloid cells in gliomas. Immunotherapeutic Strategies for the Treatment of Glioma 2022. [DOI: 10.1016/b978-0-12-819755-4.00010-2] [Reference Citation Analysis]
8 Barca C, Foray C, Hermann S, Herrlinger U, Remory I, Laoui D, Schäfers M, Grauer OM, Zinnhardt B, Jacobs AH. The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Front Immunol 2021;12:787307. [PMID: 34950148 DOI: 10.3389/fimmu.2021.787307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun 2021;12:6938. [PMID: 34836966 DOI: 10.1038/s41467-021-26940-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
10 Zhao Z, Wang Z, Song Z, Wu Y, Jin Q, Zhao Z. Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. Int Immunopharmacol 2021;101:108183. [PMID: 34649092 DOI: 10.1016/j.intimp.2021.108183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wu A, Lim M. The Challenges and Future of Immunotherapy for Gliomas. Cancer J 2021;27:371-8. [PMID: 34570451 DOI: 10.1097/PPO.0000000000000544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Qiu R, Zhong Y, Li Q, Li Y, Fan H. Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors. Front Cell Dev Biol 2021;9:693215. [PMID: 34211978 DOI: 10.3389/fcell.2021.693215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
13 Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 2021;14:63. [PMID: 33863363 DOI: 10.1186/s13045-021-01075-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
14 Dorhoi A, Kotzé LA, Berzofsky JA, Sui Y, Gabrilovich DI, Garg A, Hafner R, Khader SA, Schaible UE, Kaufmann SH, Walzl G, Lutz MB, Mahon RN, Ostrand-Rosenberg S, Bishai W, du Plessis N. Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. J Clin Invest 2020;130:2789-99. [PMID: 32420917 DOI: 10.1172/JCI136288] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
15 Haddad AF, Young JS, Aghi MK. Using viral vectors to deliver local immunotherapy to glioblastoma. Neurosurg Focus 2021;50:E4. [PMID: 33524947 DOI: 10.3171/2020.11.FOCUS20859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Haddad AF, Young JS, Mummaneni NV, Kasahara N, Aghi MK. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. J Neurooncol 2021;152:1-13. [PMID: 33389564 DOI: 10.1007/s11060-020-03684-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Foray C, Valtorta S, Barca C, Winkeler A, Roll W, Müther M, Wagner S, Gardner ML, Hermann S, Schäfers M, Grauer OM, Moresco RM, Zinnhardt B, Jacobs AH. Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Theranostics 2021;11:2020-33. [PMID: 33500706 DOI: 10.7150/thno.47269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
18 Piranlioglu R, Bradford JW, Arbab AS. Targeting tumor microenvironment-associated cells to reverse therapy resistance. New Targeting in the Reversal of Resistant Glioblastomas 2021. [DOI: 10.1016/b978-0-12-822527-1.00006-x] [Reference Citation Analysis]
19 Yin K, Xia X, Rui K, Wang T, Wang S. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression. Front Oncol 2020;10:610104. [PMID: 33384962 DOI: 10.3389/fonc.2020.610104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Ratnam NM, Frederico SC, Gonzalez JA, Gilbert MR. Clinical correlates for immune checkpoint therapy: significance for CNS malignancies. Neurooncol Adv 2021;3:vdaa161. [PMID: 33506203 DOI: 10.1093/noajnl/vdaa161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Front Immunol 2020;11:578877. [PMID: 33329549 DOI: 10.3389/fimmu.2020.578877] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
22 Richard SA. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. Dis Markers 2020;2020:8844313. [PMID: 33204365 DOI: 10.1155/2020/8844313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Dieterich LC, Bikfalvi A. The tumor organismal environment: Role in tumor development and cancer immunotherapy. Seminars in Cancer Biology 2020;65:197-206. [DOI: 10.1016/j.semcancer.2019.12.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
24 Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, Lin A, Santegoets K, Horzum U, Godinho-Santos A, Zelinskyy G, Garcia-Tellez T, Bjelica S, Taciak B, Kittang AO, Höing B, Lang S, Dixon M, Müller V, Utikal JS, Karakoç D, Yilmaz KB, Górka E, Bodnar L, Anastasiou OE, Bourgeois C, Badura R, Kapinska-Mrowiecka M, Gotic M, Ter Laan M, Kers-Rebel E, Król M, Santibañez JF, Müller-Trutwin M, Dittmer U, de Sousa AE, Esendağlı G, Adema G, Loré K, Ersvær E, Umansky V, Pollard JW, Cichy J, Brandau S. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer 2020;8:e001223. [PMID: 32907925 DOI: 10.1136/jitc-2020-001223] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
25 Davidov V, Jensen G, Mai S, Chen SH, Pan PY. Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. Front Immunol 2020;11:1842. [PMID: 32983100 DOI: 10.3389/fimmu.2020.01842] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
26 Haibe Y, El Husseini Z, El Sayed R, Shamseddine A. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. Int J Mol Sci 2020;21:E6176. [PMID: 32867025 DOI: 10.3390/ijms21176176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
27 Herbener VJ, Burster T, Goreth A, Pruss M, von Bandemer H, Baisch T, Fitzel R, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA, Strobel H. Considering the Experimental use of Temozolomide in Glioblastoma Research. Biomedicines 2020;8:E151. [PMID: 32512726 DOI: 10.3390/biomedicines8060151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
28 Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response. iScience 2020;23:101178. [PMID: 32480132 DOI: 10.1016/j.isci.2020.101178] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
29 Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol 2021;151:41-53. [PMID: 32253714 DOI: 10.1007/s11060-020-03448-1] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 24.0] [Reference Citation Analysis]
30 Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. Int J Mol Sci 2020;21:E1954. [PMID: 32182988 DOI: 10.3390/ijms21061954] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
31 Montoya ML, Kasahara N, Okada H. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neurooncol Pract 2020;7:465-76. [PMID: 33014387 DOI: 10.1093/nop/npaa007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
32 Vetsika EK, Koukos A, Kotsakis A. Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells 2019;8:E1647. [PMID: 31847487 DOI: 10.3390/cells8121647] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
33 Zhang X, Chen L, Dang WQ, Cao MF, Xiao JF, Lv SQ, Jiang WJ, Yao XH, Lu HM, Miao JY, Wang Y, Yu SC, Ping YF, Liu XD, Cui YH, Zhang X, Bian XW. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling. Lab Invest. 2020;100:619-629. [PMID: 31748682 DOI: 10.1038/s41374-019-0345-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]